ClinicalTrials.gg
CompletedNCT00599716Updated Jan 9, 2009

Safety and Efficacy Assessment of Vismed® (Sodium Hyaluronate) for the Treatment of Dry Eye Syndrome

A Phase 3 interventional study of sodium hyaluronate and vehicle in Dry Eye Disease, sponsored by Lantibio. Completed at 10 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2009-01-09.

Sponsored by Lantibio · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies testing Hyaluronic Acid in Dry Eye Syndromes — 3 open to participants now, 3 under way, none of them phase 3. Hyaluronic Acid · Dry Eye Syndromes.

Planned enrollment
2nd of 18
300 · median 88
Started
2006
the only one that year
Phase 3
2 of 18
none open now
Registered
1st of 18
by date
Lead sponsor
1 of 18
Lantibio

Among the 18 studies testing Hyaluronic Acid in Dry Eye Syndromes, this one is the 2nd largest by planned enrollment, is the only one that started in 2006, is one of 2 in phase 3, and was the 1st registered.

Dry Eye Syndromes

1,369 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.

Browse Dry Eye Syndromes studies →

Open to participants now

3 of the 18 studies testing Hyaluronic Acid in Dry Eye Syndromes are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About Hyaluronic Acid

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing Hyaluronic Acid in Dry Eye Syndromes, or all of them as a file.
02

Study summary

The study is designed to assess the safety and efficacy of Vismed®, a special eye drop containing sodium hyaluronate, in the treatment of dry eye syndrome. Vismed® is being compared to another eye drop, identical in composition except that it does not contain the active ingredient, sodium hyaluronate. This eye drop is designed as the "vehicle." Some subjects are to receive Vismed® treatment, while others are to receive the vehicle; the assignment of subjects to receive either Vismed or vehicle is to be random. The two-week treatment phase is followed by a one week follow-up period to evaluate safety of Vismed®.

Read the detailed description

VISMED® is currently marketed in Europe under the CE mark as a viscoelastic lubricant eye drop. The proprietary formulation contains a highly purified specific fraction of sodium hyaluronate. Sodium hyaluronate is a natural polymer which is also present in the structures of the human eye. Its main physical characteristic is viscoelasticity. This means that VISMED® has a high viscosity between blinks and a low viscosity during blinking ensuring efficient coating of the surface of the eye. It is believed that this protective coating of the surface of the eye helps prevent dryness and irritation. Sodium hyaluronate also possesses mucoadhesive properties and the ability to entrap water, thus resembling tear mucus glycoprotein. This, together with the coating properties of sodium hyaluronate, results in an increased pre-corneal residence time and tear film break-up time (BUT) and therefore longer lubrication of the eye surface. VISMED® is completely free of preservatives. As a result, it is non-irritating to ocular tissues and can be used frequently and for extended periods without harming the surface of the eye (e.g. without causing superficial punctate keratitis). Some preservatives are known to cause toxic or allergic reactions, the symptoms of which include stinging, burning and redness of the eyes. To further maximize patient comfort, the pH of VISMED® is adjusted to 7.3, similar to that of the natural tear film.

Hydrogels of sodium hyaluronate have been used for many years in ophthalmic surgery in Europe and the U.S. to maintain the shape of the eye, to cover surgical instruments and to protect the corneal endothelium from damage. They have unique physical properties that make them ideal for use in the treatment of Dry Eye Syndrome. Therefore, VISMED® represents a new class of compound in development for the treatment of dry eye in the US, offering lubricant properties which can alleviate the discomfort and reverse ocular damage caused by dry eye syndrome.

This study is being conducted to supplement the body of knowledge gained from studies conducted in Europe and regulatory approvals granted there to formalize the safety and efficacy of Vismed® to meet FDA requirements for a New Drug Application to market the product in the US.

03

Conditions studied

  • Dry Eye Disease

Browse trials for

Keywords

  • dry eye syndrome
  • dry eye disease
  • Vismed
  • dry eye
  • sodium hyaluronate
  • hyaluronic acid
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female adults aged 18 years and over.
  • Subjects should have at least a 3-month documented history of dry eye in both eyes diagnosed as dry eye syndrome, keratoconjunctivitis sicca (KCS), or due to Sjögren syndrome (immune exocrinopathy).
  • Subjects must agree to discontinue all artificial tears from Screening through the duration of the treatment period (Screening to Day 14).
  • Subjects who have taken Restasis® are eligible for inclusion if they have not used Restasis® during the 4 weeks prior to Screening.
  • Subjects must discontinue lens wear one week before Screening and agree not to wear contact lenses during the entire study.
  • Subjects must provide signed prior to participation in any study-related procedures.

Exclusion criteria

Exclusion Criteria:

  • Pregnancy or lactation.
  • Females of who are not using systemic , are not (≥ 1 year), or are not surgically sterilized.
  • Ocular surgery (of any type, including laser surgery) or ocular trauma within the 4 months prior to Screening.
  • Other diseases or characteristics judged by the investigator to be incompatible with the assessments needed in this study or with reliable instillation of the study medication.
  • Any active inflammation of the eye not due to KCS (eg, iritis, scleritis, etc.).
  • Participation in any other clinical trial within 30 days prior to Screening.
  • Prior participation in a previous clinical trial of Vismed®.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    1

    study drug

    Drug: sodium hyaluronate

  • Placebo comparator
    2

    vehicle control

    Drug: vehicle

Interventions

  • a sterile, unpreserved eye drop containing sodium hyaluronate in a proprietary formulation to be administered by ocular instillation

    Also known as: Vismed®, hyaluronic acid

  • Drugvehicle

    identical to proprietary formulation of active eye drop but without active ingredient, sodium hyaluronate

06

What researchers measure

Primary outcomes

  1. staining of the cornea and conjunctiva

    Time frame: Day 7

  2. symptom frequency score

    Time frame: Day 7

Secondary outcomes

  1. staining of the cornea and conjunctiva

    Time frame: Day 14

  2. symptom frequency score

    Time frame: Day 14

  3. Quality of Life assessment

    Time frame: Day 7 and Day 14

07

Study locations

10 sites
  • Florida Eye Microsurgical Institute
    Boynton Beach, Florida 33426, United States
  • Center for Excellence in Eye Care
    Miami, Florida 33176, United States
  • East Florida Eye Institutue
    Stuart, Florida 34994, United States
  • Abrams Eye Center
    Stuart, Florida 44115, United States
  • International Eye Center
    Tampa, Florida 33603, United States
  • American Eye Institute
    New Albany, Indiana 47150, United States
  • Comprehensive Eye Care
    Washington, Missouri 63090, United States
  • Charlotte Eye, Ear, Nose and Throat
    Charlotte, North Carolina 28210, United States
  • Ophthalmic Research & Clinical Studies
    Moon Twp, Pennsylvania 15108, United States
  • Chattanooga Eye Institute
    Chattanooga, Tennessee 37411, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2006, a primary completion of Apr 2008 and a completion of May 2008. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 11, 2008
First posted
Jan 24, 2008
Start
Dec 2006
Primary completionActual
Apr 2008
CompletionActual
May 2008
Last update
Jan 9, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 9, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00599716
Lead sponsor
Lantibio
Collaborators
River Plate Biotechnology, Inc., Rx Development Resources, LLC
First posted
Jan 24, 2008
Start date
Dec 2006
Primary completion
Apr 2008
Completion
May 2008
Last update
Jan 9, 2009

Study contacts

Roger Vogel, MD
study chair · Rx Development Resources, LLC
Terry Laliberte, BS
study director · River Plate Biotechnology, Inc.
Charles (Andy) Kirby, MD
principal investigator · Chattanooga Eye Institute, Chattanooga, TN
Mark Abrams, MD
principal investigator · Abrams Eye Center, Cleveland, OH

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Hyaluronic Acid

Start the discussion